← Back to Search

Hormone Therapy

Trans man for Gender Dysphoria

N/A
Recruiting
Led By Merve OGULMUS, SLP.
Research Sponsored by Hacettepe University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up change from 4th to the 8th dose of hormone treatment
Awards & highlights
No Placebo-Only Group

Summary

The aim of the study is to follow acoustic and perceptual voice changes in trans men during hormone therapy and to examine the relationship between psychosocial and vocal characteristics and testosterone measured in routine follow-up in accordance with international follow-up guidelines.

Eligible Conditions
  • Gender Dysphoria
  • Transgender
  • Hormone Replacement Therapy

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~change from 4th to the 8th dose of hormone treatment
This trial's timeline: 3 weeks for screening, Varies for treatment, and change from 4th to the 8th dose of hormone treatment for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Change in Self-perception of voice
Secondary study objectives
Change in Acoustic Voice Characteristics
Change in testosterone level
Anxiety
+4 more

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: Trans manExperimental Treatment1 Intervention
"Trans man" is assigned female at birth and identify as man

Find a Location

Who is running the clinical trial?

Hacettepe UniversityLead Sponsor
839 Previous Clinical Trials
112,779 Total Patients Enrolled
Merve OGULMUS, SLP.Principal InvestigatorHacettepe University, Speech and Language Therapy
Koray Baser, Assoc. Prof.Study ChairHacettepe Univeristy, Faculty of Medicine, Mental Health and Disease Department
~0 spots leftby Jan 2025